Imperial College London Featured PhD Programmes
IST Austria Featured PhD Programmes
London School of Economics and Political Science Featured PhD Programmes

The co-design of safe deprescribing interventions, shared decision-making tools and resources in primary care for use with elderly patients and other vulnerable patients with multi-morbidities and polypharmacy in the North West Coast

   Applied Health Research Hub

This project is no longer listed on and may not be available.

Click here to search for PhD studentship opportunities
  Dr Alison Doherty, Dr Josephine Gibson, Prof Andrea Manfrin  No more applications being accepted  Funded PhD Project (UK Students Only)

Preston United Kingdom Pharmaceutical Chemistry Pharmacology Pharmacy

About the Project

Supervisory Team: Dr Alison Doherty, Dr Josephine Gibson, Professor Andrea Manfrin

Contact: [Email Address Removed]

Theme: Methodological Innovation, Development, Adaptation and Support (MIDAS)

Lay Summary: `Polypharmacy’ is a term used to describe the concurrent use of many medications by a patient to treat their coexisting multiple health conditions. `Multimorbidity’ is a term used to describe concurrent multiple health conditions. Polypharmacy and multimorbidity is a growing concern for healthcare systems locally, regionally, nationally, and internationally. It affects some of the most vulnerable in society, often contributing to health inequalities. Although the elderly (aged over 65 years) are most affected, people with learning disabilities, younger people, and those from deprived communities may also have to use multiple concurrent medications for their multiple co-existing health conditions.

Whilst polypharmacy may be appropriate in managing complex or multiple conditions, it can present risks and it can be an ineffective use of resources. One way to address it is through a process known as `safe deprescribing’. This involves a process of identifying and discontinuing one or more prescribed medications when existing or potential harms outweigh existing or potential benefits of those medications. Care for patients with polypharmacy mainly takes place in primary care with the General Practitioner (GP) taking a vital role in managing a patient’s medication. In 2020, ARC NWC published a review of barriers and facilitators to safe deprescribing interventions for patients, carers, and prescribers. The review found several barriers such as a lack of evidence-based guidance for the care of older people with multimorbidity, and a lack of shared communication, decision-making tools, and resources.

The overall aim of this proposed PhD programme of study is to explore how safe deprescribing interventions, shared decision-making tools and resources in primary care can be tailored for older people, and other vulnerable patients, with multimorbidity and polypharmacy in the North West Coast.

Application Process: Completed application forms and a fully completed research proposal (not more than 1000 words excluding references) related to the title you are applying for should be returned to the Research Student Registry by email [Email Address Removed] quoting the appropriate studentship reference number (RS/21/18). Potential applicants must:

  • consult the HIAT and demonstrate consideration of the toolkit in their research proposal
  • discuss their research proposal with the appropriate Director of Studies (DoS) prior to application
  • state the title of the project(s) they are applying for, and the preferred mode of study (PhD via MPhil, or MPhil) where indicated on the application form.

Application forms received without this information will not be considered.

Funding Notes

There are two studentship funding options available for this project: PhD (via MPhil) 3 years full-time; MPhil 2 years full-time. Please state your preferred mode of study on the application form.
PhD saved successfully
View saved PhDs